ORCL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Oracle Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Oracle Corporation · Technology
$149.12
+45.0% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
ORCL has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ORCL |
PFE |
| Current Price |
$149.12 |
$27.64 |
| Fair Value Estimate |
$216.22 |
$30.94 |
| Upside to Fair Value |
+45.0%
|
+12.0%
|
| Market Cap |
$429.5B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
14.6x
|
17.4x
|
| Price / Sales |
6.0x
|
2.5x
|
| Price / FCF |
—
|
14.3x
|
| Revenue Growth YoY |
+29.6%
|
+2.6%
|
| Gross Margin |
63.9%
|
71.3%
|
| Operating Margin |
32.4%
|
25.1%
|
| Return on Equity |
42.6%
|
4.9%
|
| Dividend Yield |
1.34% |
6.22% |
| FCF Yield |
—
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Oracle is a global enterprise software and cloud infrastructure provider whose portfolio spans the Oracle Database, Java, Fusion Cloud SaaS applications (ERP, EPM, SCM, HCM), NetSuite, and Oracle Cloud Infrastructure, sold through a direct sales force to businesses, governments, and educational institutions worldwide. The business quality is high on fundamentals: trailing-twelve-month gross margi…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
ORCL |
PFE |
| Zone Low |
$162.16 |
$23.21 |
| Zone High |
$183.79 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|